TipRanks
Advertisement
Advertisement

ABSI Stock Latest News

Analyst Maintains Buy on AbSci as ABS-201’s Differentiated Profile Supports Unchanged $16 Price Target
RatingsAnalyst Maintains Buy on AbSci as ABS-201’s Differentiated Profile Supports Unchanged $16 Price Target
4d ago
ABSI
Absci price target raised to $20 from $16 at KeyBanc
PremiumThe Fly
Absci price target raised to $20 from $16 at KeyBanc
8d ago
ABSI
Absci price target raised to $15 from $14 at JPMorgan
PremiumThe Fly
Absci price target raised to $15 from $14 at JPMorgan
12d ago
ABSI
Absci Maintained at Buy as Analyst Sees Significant Endometriosis Upside, Keeps $16 Price Target Unchanged
PremiumRatings
Absci Maintained at Buy as Analyst Sees Significant Endometriosis Upside, Keeps $16 Price Target Unchanged
30d ago
ABSI
Absci announces preliminary details for Phase 2 Storyline trial of ABS-201
PremiumThe Fly
Absci announces preliminary details for Phase 2 Storyline trial of ABS-201
1M ago
ABSI
Absci initiated with an Outperform at LifeSci Capital
PremiumThe FlyAbsci initiated with an Outperform at LifeSci Capital
2M ago
ABSI
Absci price target raised to $15 from $13 at BTIG
Premium
The Fly
Absci price target raised to $15 from $13 at BTIG
2M ago
ABSI
Absci reports Q2 EPS (21c), consensus (20c)
Premium
The Fly
Absci reports Q2 EPS (21c), consensus (20c)
2M ago
ABSI
Closing Bell Movers: CoreWeave spikes 17% on results and outlook
PremiumThe Fly
Closing Bell Movers: CoreWeave spikes 17% on results and outlook
2M ago
HRB
SVV
Analyst Reiterates Buy on ABSI, Sees Upside Ahead of ABS-201 Readout with ATLAS AI Platform Support and Unchanged $16 Price Target
PremiumRatings
Analyst Reiterates Buy on ABSI, Sees Upside Ahead of ABS-201 Readout with ATLAS AI Platform Support and Unchanged $16 Price Target
2M ago
ABSI
AbSci: Buy Rating Reaffirmed as ABS-201 Hair-Loss Program Advances; $11 Price Target Maintained
PremiumRatings
AbSci: Buy Rating Reaffirmed as ABS-201 Hair-Loss Program Advances; $11 Price Target Maintained
2M ago
ABSI
Absci: Buy Rating Backed by Promising ABS-201 Early Data and Strengthened Cash Runway to 2028
PremiumRatings
Absci: Buy Rating Backed by Promising ABS-201 Early Data and Strengthened Cash Runway to 2028
2M ago
ABSI
Absci Corp. Earnings Call Highlights ABS-201 And Cash
PremiumCompany AnnouncementsAbsci Corp. Earnings Call Highlights ABS-201 And Cash
2M ago
ABSI
Absci Highlights Positive Phase 1 Data and Financing
Premium
Company Announcements
Absci Highlights Positive Phase 1 Data and Financing
2M ago
8K
ABSI
ABSI Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
ABSI Upcoming Earnings Report: What to Expect?
3M ago
ABSI
Absci Maintained at Buy as Yazdi Highlights ABS-201’s Dual Alopecia and Endometriosis Upside; $13 Price Target Unchanged
PremiumRatings
Absci Maintained at Buy as Yazdi Highlights ABS-201’s Dual Alopecia and Endometriosis Upside; $13 Price Target Unchanged
3M ago
ABSI
Absci management to meet virtually with KeyBanc
PremiumThe Fly
Absci management to meet virtually with KeyBanc
3M ago
ABSI
ASE, ProQR, AbSci, Ultragenyx, YPF: Insider Turmoil
PremiumWeekend Updates
ASE, ProQR, AbSci, Ultragenyx, YPF: Insider Turmoil
4M ago
ASX
YPF
Absci director buys $149K in common stock
PremiumThe Fly
Absci director buys $149K in common stock
4M ago
ABSI
AbSci: Buy Rating Backed by Proprietary Wet‑Lab Data Moat and Emerging Validation of AI‑Enabled Biologic Design
PremiumRatingsAbSci: Buy Rating Backed by Proprietary Wet‑Lab Data Moat and Emerging Validation of AI‑Enabled Biologic Design
4M ago
ABSI
Absci price target raised to $10 from $4.10 at Morgan Stanley
Premium
The Fly
Absci price target raised to $10 from $4.10 at Morgan Stanley
4M ago
ABSI
Absci: Clean Phase 1 Data, Strengthened ABS-201 Outlook Drive Price Target Increase from $9 to $13 and Buy Rating
Premium
Ratings
Absci: Clean Phase 1 Data, Strengthened ABS-201 Outlook Drive Price Target Increase from $9 to $13 and Buy Rating
4M ago
ABSI

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >